{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:06:52Z","timestamp":1792026412539,"version":"4.4.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cases of 3 patients with Cushing's disease who developed long-term adrenal insufficiency after discontinuation of prolonged osilodrostat therapy were recently described for the first time. We report 2 additional cases of persistent prolonged adrenal insufficiency after discontinuation of osilodrostat treatment for intense hypercortisolism due to Cushing's disease and ectopic ACTH syndrome. In addition, we show for that adrenal insufficiency in these patients was associated with low\/normal 11-deoxycortisol concentrations despite high plasma ACTH concentrations. These results suggest that CYP11B1 is not the only target of osilodrostat and that, in vivo, osilodrostat has other prolonged and strong inhibitory effect on adrenal steroidogenesis upstream of CYP11B1. Knowledge of this remnant effect is important for the care of patients with Cushing's syndrome treated with osilodrostat. Further studies are needed to clarify the frequency and the mechanisms of this remnant effect.<\/jats:p>","DOI":"10.1093\/ejendo\/lvad167","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T22:43:19Z","timestamp":1703112199000},"page":"L1-L3","source":"Crossref","is-referenced-by-count":35,"title":["Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-7868","authenticated-orcid":false,"given":"Amandine","family":"Ferriere","sequence":"first","affiliation":[{"name":"Service d'endocrinologie, diab\u00e8te et nutrition, CHU de Bordeaux , Avenue Magellan , 33600 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Salenave","sequence":"additional","affiliation":[{"name":"Service d\u2019endocrinologie, H\u00f4pital Bic\u00eatre APHP , B\u00e2timent Paul Broca, 78, avenue du G\u00e9n\u00e9ral Leclerc , 94270 Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Puerto","sequence":"additional","affiliation":[{"name":"Service d'endocrinologie, diab\u00e8te et nutrition, CHU de Bordeaux , Avenue Magellan , 33600 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Young","sequence":"additional","affiliation":[{"name":"Service d\u2019endocrinologie, H\u00f4pital Bic\u00eatre APHP , B\u00e2timent Paul Broca, 78, avenue du G\u00e9n\u00e9ral Leclerc , 94270 Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-3306","authenticated-orcid":false,"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Service d'endocrinologie, diab\u00e8te et nutrition, CHU de Bordeaux , Avenue Magellan , 33600 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"6","key":"2024013107252284800_lvad167-B1","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","article-title":"Prolonged adrenocortical blockade following discontinuation of osilodrostat","volume":"188","author":"Poirier","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2024013107252284800_lvad167-B2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-020-01277-0","article-title":"Osilodrostat: first approval","volume":"80","author":"Duggan","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"2024013107252284800_lvad167-B3","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024013107252284800_lvad167-B4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cen.14551","article-title":"Osilodrostat in Cushing's disease: the risk of delayed adrenal insufficiency should be carefully monitored","volume":"98","author":"Castinetti","year":"2023","journal-title":"Clin Endocrinol"},{"issue":"9","key":"2024013107252284800_lvad167-B5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2024013107252284800_lvad167-B6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2024013107252284800_lvad167-B7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-8587(23)00150-X","article-title":"Diagnostic challenges in cyclic Cushing's syndrome: a systematic review","volume":"11","author":"Nowak","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2024013107252284800_lvad167-B8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad167\/54705122\/lvad167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/L1\/55371493\/lvad167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/L1\/55371493\/lvad167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T02:25:29Z","timestamp":1706667929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/1\/L1\/7484585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad167","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,20]]}}}